#United States #San Diego #Triumvira #SITC #T Cell

Triumvira Immunologics to Present at SITC Conference

Triumvira Immunologics, a company focused on advancing T cell therapy, will present key findings from its ongoing clinical trials at the upcoming 2025 SITC (Society for Immunotherapy of Cancer) Spring Scientific, Cellular Therapy and Solid Tumors Conference in San Diego, California. Scheduled for March 12-14, this event will spotlight the latest advancements in cancer immunotherapy, particularly in treating solid tumors using novel therapeutic approaches.

The company, which is currently in its clinical stage, has been making significant strides with its pioneering autologous and allogeneic T cell therapeutics. These therapies harness the natural capabilities of T cells to target and treat solid tumors, a critical area of unmet need in oncology.

Overview of the Presentation

Triumvira will showcase interim results from the Phase 1/2 study titled "A Phase 1/2 Study on the Safety and Efficacy of Autologous TAC T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors." This study seeks to determine both the safety and effectiveness of the company's unique T cell therapies, which specifically target Claudin 18.2, a tumor-associated antigen expressed in certain advanced solid tumors such as gastric cancer.

Details of the Abstract Presentation

• - Abstract Number: 28
• - Abstract Title: A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with Claudin 18.2+ advanced solid tumors
• - Authors: Ecaterina E. Dumbrava, Syma Iqbal, Simon Turcotte, Gregory Botta, Benjamin Schlechter, Geoffrey Ku, Peter Hosein, Sam Saibil, Miriam Gavriliuc, Maria Apostolopoulou, Mobolaji Giwa, Kara Moss, Swaminathan Murugappan, Davendra Sohal
• - Date: Thursday, March 13, 2025, at 4:05 PM PDT

This presentation is particularly significant given the pressing need for effective treatments in patients who have not responded to traditional therapies. The TACTIC-3 trial (NCT05862324), which serves as the basis for this abstract, investigates TAC101-CLDN18.2's therapeutic potential in a population with advanced solid tumors that have shown limited responsiveness to previous treatments—specifically those having undergone two or more lines of therapy.

Insights from the President

Robert Williamson, President of Triumvira Immunologics, expressed his enthusiasm regarding the findings to be presented at the conference. He stated, "We are excited to share the latest clinical data from our ongoing TACTIC-3 study. These interim findings further reinforce the potential of our TAC technology to deliver safe and effective cell therapies for patients with Claudin 18.2+ advanced solid tumors."

Williamson emphasized the importance of innovation in T cell therapies, noting the challenges many patients face with limited treatment options. By leveraging the natural functionality of T cells, Triumvira aims to provide viable alternatives that may enhance survival rates and overall quality of life for cancer patients.

About Triumvira Immunologics

Triumvira Immunologics, Inc. is distinguished by its development of cutting-edge, non-gene-edited T cell therapies that represent a first-in-class approach in addressing solid tumors. With operations based in San Diego, California, Austin, Texas, and Hamilton, Ontario, Triumvira is committed to advancing T cell therapies that are intended to activate the body's immune response more effectively than existing therapies like CAR-T and engineered T cell receptor (TCR) therapies.

The company continues to work on a robust pipeline, targeting various promising tumor-associated antigens such as Claudin 18.2, HER2, GUCY2C, and GPC3. Triumvira’s commitment to innovation exemplifies its mission of bringing new hope to patients battling cancer.

For more information about their research and upcoming presentations, individuals can visit Triumvira's official site or follow them on social media platforms such as LinkedIn and X.